Tea tree oil for Demodex blepharitis

K Savla, JT Le, AD Pucker - Cochrane Database of Systematic …, 2020 - cochranelibrary.com
Antecedentes La blefaritis por Demodex es una enfermedad crónica comúnmente asociada
con síntomas de ojo seco recalcitrante, aunque muchas personas con ácaros Demodex son …

[HTML][HTML] The efficacy of intense pulsed light combined with meibomian gland expression for the treatment of dry eye disease due to meibomian gland dysfunction: a …

X Yan, J Hong, X Jin, W Chen, B Rong, Y Feng… - Eye & contact …, 2021 - journals.lww.com
Objectives: To compare the efficacy of intense pulsed light (IPL) combined with Meibomian
gland expression (MGX), and instant warm compresses combined with MGX, for treatment of …

[HTML][HTML] Reliability of Chinese web-based ocular surface disease index questionnaire in dry eye patients: a randomized, crossover study

XM Zhang, LT Yang, Q Zhang, QX Fan… - International journal …, 2021 - ncbi.nlm.nih.gov
AIM To assess the reliability of web-based version of ocular surface disease index in
Chinese (C-OSDI) on clinically diagnosed dry eye disease (DE) patients. METHODS A total …

[HTML][HTML] Dry eye disease in the young: A narrative review

F Stapleton, FG Velez, C Lau, JS Wolffsohn - The ocular surface, 2023 - Elsevier
Dry eye disease (DED), a multifactorial ocular disease that significantly impacts quality of
life, is most commonly reported in adults. This review describes the prevalence, risk factors …

Latest evidences on meibomian gland dysfunction diagnosis and management

E Villani, L Marelli, A Dellavalle, M Serafino, P Nucci - The ocular surface, 2020 - Elsevier
Meibomian gland dysfunction (MGD) can be considered the leading cause of dry eye
disease (DED) and one of the most common ophthalmic disorders found in clinical practice …

Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent

A Ballesteros-Sanchez, C De-Hita-Cantalejo… - The Ocular Surface, 2023 - Elsevier
Abstract Perfluorohexyloctane (F6H8), a physically and chemically inert synthetic
compound, has recently emerged as a promising candidate for the treatment of DED due to …

Efficacy and safety of treatment of hyposecretory dry eye with platelet‐rich plasma

V García‐Conca, M Abad‐Collado… - Acta …, 2019 - Wiley Online Library
Objective To evaluate and compare the symptomatology and clinical findings in
hyposecretory dry eye of the treatment with platelet‐rich plasma (PRP) and artificial tears of …

Altered ocular surface immune cell profile in patients with dry eye disease

AP Nair, S D'Souza, R Shetty, P Ahuja, G Kundu… - The Ocular Surface, 2021 - Elsevier
Purpose Aberrant inflammation and immune dysregulation are known pathogenic
contributors in dry eye disease (DED). Aim of the study was to determine the proportions of …

Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies

M Korenfeld, KK Nichols, D Goldberg, D Evans, K Sall… - Cornea, 2021 - journals.lww.com
Purpose: The safety of KPI-121 0.25%, an ophthalmic nanoparticle suspension of
loteprednol etabonate, was evaluated in subjects with dry eye disease (DED) in one phase …

Efficacy of marine ω-3 fatty acid supplementation vs placebo in reducing incidence of dry eye disease in healthy US adults: a randomized clinical trial

WG Christen, NR Cook, JAE Manson… - JAMA …, 2022 - jamanetwork.com
Importance Results of several small randomized clinical trials have suggested that
supplements of marine ω-3 fatty acids may be beneficial in treating signs and symptoms of …